Although mutual fund managers have been aggressive buyers over the past few months, the lofty valuations at present are making them wary. The benchmark Nifty last week fell just few points short of touching a new all-time high. Industry players say several fund managers have already increased their cash levels. However, as there is a limit on increasing cash vis-à-vis their fund corpus, they are turning to defensive stocks. Pharmaceutical companies such as Sun Pharmaceutical, Cipla, Lupin, Sanofi and Aurobindo Pharma are seeing some buying interest from fund managers. Also, shares ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?